Profile data is unavailable for this security.
About the company
Genscript Biotech Corporation is a Hong Kong-based investment holding company principally engaged in life science research and related businesses. The Company operates through four segments. Life Sciences Research Services segment includes gene and peptide synthesis, deoxyribonucleic acid (DNA) and primer synthesis, DNA sequencing, customized antibody production, protein expression and the production of stable cell lines. Preclinical Drug Development Services segment includes protein and antibody engineering, the study of in vitro drug and the study of in vivo drug. Life Sciences Research Catalog Products segment provides antibodies, recombinant proteins, equipment for protein isolation and analysis, molecular biology reagents, peptide, biochemicals and stable cell lines. Industrial Synthetic Biology Products segment is engaged in the development and production of industrial enzymes.
- Revenue in HKD (TTM)6.57bn
- Net income in HKD-747.37m
- Incorporated2015
- Employees6.94k
- LocationGenscript Biotech CorpNo. 28Yongxi Road, Jiangning Science ParkNANJING ChinaCHN
- Phone+86 2 558897288
- Fax+86 2 558897288
- Websitehttps://www.genscript.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Simcere Pharmaceutical Group Ltd | 7.14bn | 772.86m | 13.83bn | 7.03k | 18.28 | 1.78 | 12.50 | 1.94 | 0.2899 | 0.2899 | 2.74 | 2.98 | 0.6106 | 3.53 | 2.65 | 1,016,775.00 | 6.60 | 10.17 | 8.94 | 15.60 | 75.43 | 78.82 | 10.80 | 17.50 | 1.87 | 0.9742 | 0.1652 | 46.68 | 4.49 | 7.92 | -23.22 | -0.5213 | 23.93 | -- |
| SSY Group Ltd | 6.46bn | 1.32bn | 14.22bn | 5.60k | 10.82 | 2.05 | 8.13 | 2.20 | 0.4427 | 0.4427 | 2.17 | 2.33 | 0.5637 | 3.00 | 3.01 | 1,154,109.00 | 11.59 | 10.51 | 15.58 | 14.03 | 56.01 | 58.72 | 20.57 | 18.62 | 1.60 | 29.61 | 0.317 | 38.56 | 0.4505 | 9.10 | 17.44 | 7.66 | 3.94 | 13.56 |
| 3SBio Inc | 8.45bn | 1.68bn | 14.83bn | 5.41k | 9.01 | 0.961 | 7.14 | 1.75 | 0.6751 | 0.6751 | 3.46 | 6.33 | 0.3426 | 1.58 | 6.75 | 1,561,857.00 | 6.95 | 7.44 | 9.03 | 9.29 | 84.98 | 82.91 | 20.30 | 21.50 | 2.26 | 5.26 | 0.2266 | -- | 13.84 | 11.26 | -19.13 | 3.94 | -- | -- |
| Grand Pharmaceutical Group Ltd | 10.53bn | 1.88bn | 15.33bn | 10.53k | 8.07 | 0.998 | 6.70 | 1.46 | 0.5356 | 0.5356 | 3.00 | 4.33 | 0.4692 | 2.94 | 5.06 | 999,581.40 | 8.45 | 10.09 | 11.66 | 14.01 | 61.96 | 61.97 | 18.00 | 22.35 | 0.9819 | 23.21 | 0.1831 | 26.95 | 10.12 | 12.06 | -9.59 | 21.41 | -- | 24.77 |
| The United Laboratories Intl. Hldgs Ltd. | 14.86bn | 2.92bn | 17.23bn | 15.00k | 5.90 | 1.25 | 4.88 | 1.16 | 1.61 | 1.61 | 8.18 | 7.58 | 0.6871 | 3.36 | 3.26 | 990,442.40 | 13.51 | 7.89 | 20.52 | 12.64 | 46.11 | 44.17 | 19.66 | 12.73 | 1.74 | -- | 0.1055 | 15.51 | 21.22 | 12.84 | 70.85 | 31.66 | -- | 14.67 |
| China Traditional Chinese Med Hldg CoLtd | 19.59bn | 1.39bn | 21.65bn | 17.30k | 15.58 | 0.9464 | 8.01 | 1.11 | 0.2759 | 0.2759 | 3.89 | 4.54 | 0.4986 | 1.47 | 2.09 | 1,132,450.00 | 3.84 | 4.60 | 5.85 | 7.07 | 51.18 | 57.07 | 7.70 | 9.77 | 1.48 | 8.01 | 0.1773 | -- | 26.69 | 9.99 | 68.11 | -2.24 | -- | -- |
| Genscript Biotech Corp | 6.57bn | -747.37m | 23.41bn | 6.94k | -- | 2.15 | -- | 3.56 | -0.3548 | -0.3548 | 3.12 | 5.13 | 0.283 | 7.59 | 5.45 | 947,323.20 | -11.97 | -18.34 | -18.27 | -26.15 | 48.78 | 54.68 | -42.30 | -64.91 | 4.65 | -- | 0.1694 | -- | 34.17 | 29.44 | 57.91 | -- | 17.14 | -- |
| WuXi XDC Cayman Inc | 2.30bn | 306.58m | 24.55bn | 1.18k | 78.80 | 4.10 | 65.17 | 10.69 | 0.2602 | 0.2602 | 1.95 | 5.00 | -- | -- | -- | 1,949,458.00 | -- | -- | -- | -- | 26.35 | -- | 13.35 | -- | 4.03 | -- | 0.0005 | -- | 114.44 | -- | 82.07 | -- | -- | -- |
| HUTCHMED (China) Ltd | 6.56bn | 788.88m | 26.44bn | 1.99k | 33.74 | 4.62 | 30.91 | 4.03 | 0.8994 | 0.8994 | 7.63 | 6.56 | 0.7258 | 7.19 | 7.69 | 3,299,600.00 | 8.76 | -14.35 | 13.36 | -20.43 | 54.12 | 36.57 | 12.06 | -31.44 | 2.60 | -- | 0.1038 | -- | 96.52 | 31.38 | 127.93 | -- | 38.65 | -- |
| RemeGen Co Ltd | 1.16bn | -1.63bn | 27.44bn | 3.62k | -- | 4.43 | -- | 23.58 | -3.03 | -3.03 | 2.16 | 6.88 | 0.1864 | 0.4005 | 3.46 | 321,880.00 | -26.17 | -18.66 | -31.75 | -23.75 | 76.48 | 81.94 | -140.43 | -102.88 | 1.31 | -64.00 | 0.2682 | -- | 40.16 | 148.65 | -51.30 | -- | -- | -- |
Data as of Apr 26 2024. Currency figures normalised to Genscript Biotech Corp's reporting currency: Hong Kong Dollar HKD
8.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 05 Apr 2024 | 38.10m | 1.79% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 26.36m | 1.24% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 24.02m | 1.13% |
| GF Fund Management Co., Ltd.as of 30 Jun 2023 | 21.49m | 1.01% |
| Foresight Fund Management Co., Ltd.as of 30 Jun 2023 | 11.62m | 0.55% |
| E Fund Management Co., Ltd.as of 30 Jun 2023 | 11.20m | 0.53% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2023 | 11.09m | 0.52% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2023 | 10.69m | 0.50% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2023 | 10.52m | 0.50% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2023 | 10.28m | 0.48% |
More ▼
Data from 30 Jun 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
